A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

Key facts

Study ID: NCT05938270
Run by: AstraZeneca
People needed: 113
Starts: 2023-09-21
Expected to finish: 2026-06-15
Last updated by the study team: 2026-06-30

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

male participants >/= 18 years old
participants deemed suitable for radical prostatectomy
participants with localised prostate cancer with unfavourable intermediate/high/very high risk eligible for prostatectomy
adequate organ and marrow function as per protocol
capable of giving signed informed consent
For participants participating in the Optional Genetic Research Only: Provision of signed and dated written Optional Genetic Research Information
Available FFPE diagnostic tumour biopsy samples
Participants must use a condom (with spermicide) from screening to 6 months after screening and refrain from fathering a child or donating sperm

You may not qualify if…

As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including, active bleeding diatheses, or active infection including HepB, hepatitis C and HIV. Screening for chronic conditions is not required.
Active HBV is defined by a known positive HBsAg result. Participants with a past or resolved HBV infection (defined as the presence of HepB antibody and absence of HBsAg) are eligible.
Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
Participants with any known predisposition to bleeding (eg, active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).
Participants with history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no Clinical MDS/AML suspicion, no specific screening for MDS/AML (by bone marrow/bone biopsy) is required.
Prior malignancy within 3 years of screening whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.
Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of TdP.
Any of the following cardiac criteria:
Mean resting corrected QT interval (QTcF) > 450 milliseconds or QTcF < 340 milliseconds obtained from triplicate ECGs and averaged, recorded within 5 minutes.
Any factors that increase the risk of QT prolongation, shortening or risk of arrhythmic events such as hypokalaemia, congenital long or short QT syndrome, family history of long QT syndrome, familial short QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong or shorten the QT interval.
Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, second or third degree atrioventricular block and clinically significant sinus node dysfunction not treated with pacemaker.
Other CVS diseases as defined by any of the following:
Symptomatic heart failure (as defined by NYHA class ≥ 2).
uncontrolled hypertension.
hypertensive heart disease with significant left ventricular hypertrophy.
History of acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention or coronary artery bypass grafting within 6 months prior to screening.
cardiomyopathy of any aetiology.
presence of clinically significant valvular heart disease.
history of atrial or ventricular arrhythmia requiring acute treatment; participants with atrial fibrillation and optimally controlled ventricular rate (heart rate < 100 bpm) are permitted.
transient ischaemic attack, or stroke within 6 months prior to screening.
participants with symptomatic hypotension at screening.
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Saruparib (AZD5305).
History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening. Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.
Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).
Prior treatment with any systemic or localised anti-cancer treatment for the localised prostate cancer.

Where it is running

Research Site — Detroit, Michigan, United States
Research Site — Providence, Rhode Island, United States
Research Site — Melbourne, Australia
Research Site — South Brisbane, Australia
Research Site — Vancouver, British Columbia, Canada
Research Site — Toronto, Ontario, Canada
Research Site — Québec, Quebec, Canada
Research Site — Amsterdam, Netherlands
Research Site — Nijmegen, Netherlands
Research Site — Barcelona, Spain
Research Site — Barcelona, Spain
Research Site — Madrid, Spain
Research Site — Valencia, Spain
Research Site — Cambridge, United Kingdom
Research Site — Manchester, United Kingdom
Research Site — Newcastle upon Tyne, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.